Exercise period of Brighter Warrants TO3, April 11-25.
As part of our financing strategy and the agreement with L1 Capital, Brighter has distributed free warrants to the company's shareholders to reduce dilution.
During the period of April 11 to April 25, 2018, holders of TO3 Warrants can exercise the Warrants and subscribe for new shares. One (1) TO3 warrant can be exchanged for one (1) share, at a price of SEK 4.00.
Holders of warrants TO3 who have their Warrants registered in custody at a bank or fund commissioner shall contact their bank or fund commissioner, e.g. Avanza (+46-8-562 250 00) or Nordnet (+46-8-806 330 00), if they want to exercise the Warrants and subscribe for the corresponding shares.
Exercise of the Warrants and subscription of shares for direct registered holders of Warrants takes place through simultaneous payment and submittal of the registered application form, signed and submitted to the Company’s share agent no later than 16:00 CET on April 25, 2018. The Company’s share agent is Eminova Fondkommission, which can be contacted by phone at 08-684 211 00 or by email at info@eminova.se.
For complete terms and conditions of the Warrants, please visit: https://brighter.se/en/investors/documents/.
For more information, please contact:
Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Email: truls.sjostedt@brighter.se
Ann Zetterberg, CFO
Tel: +46 708 37 21 23
Email: ann.zetterberg@brighter.se
About Brighter
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of the most serious healthcare problems: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and close associates, healthcare providers, research, pharmaceutical industry and society. www.brighter.se
About Actiste
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injection, and automatic logging and timing of all activity are done in a single unit. Actiste is connected via an autonomous and secure mobile connection, the information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed.
Validated user-generated data, such as glucose levels or insulin doses, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives ' concerns, and release enormous healthcare resources. www.actiste.com
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic Holding AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.
